The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 18, Issue 4, Pages 385-400
Publisher
Bioscientifica
Online
2011-05-07
DOI
10.1530/erc-11-0045
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study
- (2015) Soha Salama El Sheikh et al. NEOPLASIA
- Androgen receptor levels are upregulated by Akt in prostate cancer
- (2011) S. Ha et al. ENDOCRINE-RELATED CANCER
- Targeting the Akt/mTOR pathway in Brca1-deficient cancers
- (2011) T Xiang et al. ONCOGENE
- Docetaxel-based combination therapy for castration-resistant prostate cancer
- (2010) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Genipin Induced Apoptosis Associated with Activation of the c-Jun NH2-Terminal Kinase and p53 Protein in HeLa Cells
- (2010) Houli Cao et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
- (2010) E Di Gennaro et al. BRITISH JOURNAL OF CANCER
- Reactive Oxygen Species-Dependent Apoptosis by Gugulipid Extract of Ayurvedic Medicine Plant Commiphora mukul in Human Prostate Cancer Cells Is Regulated by c-Jun N-Terminal Kinase
- (2010) D. Xiao et al. MOLECULAR PHARMACOLOGY
- The Bioactive Compounds α-Chaconine and Gallic Acid in Potato Extracts Decrease Survival and Induce Apoptosis in LNCaP and PC3 Prostate Cancer Cells
- (2010) Lavanya Reddivari et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
- (2010) Christoph W. M. Reuter et al. WORLD JOURNAL OF UROLOGY
- The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
- (2009) R Diaz et al. BRITISH JOURNAL OF CANCER
- Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
- (2008) Mari Nakabayashi et al. BJU INTERNATIONAL
- Cost-effectiveness of prostate cancer chemoprevention
- (2008) Robert S. Svatek et al. CANCER
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
- (2008) Q. Xue et al. CANCER RESEARCH
- The current state of preclinical prostate cancer animal models
- (2008) Kenneth J. Pienta et al. PROSTATE
- Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors
- (2008) Claudio Festuccia et al. PROSTATE
- A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
- (2007) Robert W. Ross et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation